Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.

Citrome L, Holt RI, Walker DJ, Hoffmann VP.

Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000. Review.

PMID:
21495734
2.

Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.

Cuerda C, Merchan-Naranjo J, Velasco C, Gutierrez A, Leiva M, de Castro MJ, Parellada M, Giráldez M, Bretón I, Camblor M, García-Peris P, Dulín E, Sanz I, Desco M, Arango C.

Clin Nutr. 2011 Oct;30(5):616-23. doi: 10.1016/j.clnu.2011.03.007. Epub 2011 Apr 13.

PMID:
21492975
3.

Deletion of CDKAL1 affects mitochondrial ATP generation and first-phase insulin exocytosis.

Ohara-Imaizumi M, Yoshida M, Aoyagi K, Saito T, Okamura T, Takenaka H, Akimoto Y, Nakamichi Y, Takanashi-Yanobu R, Nishiwaki C, Kawakami H, Kato N, Hisanaga S, Kakei M, Nagamatsu S.

PLoS One. 2010 Dec 9;5(12):e15553. doi: 10.1371/journal.pone.0015553.

4.

Genomics, type 2 diabetes, and obesity.

McCarthy MI.

N Engl J Med. 2010 Dec 9;363(24):2339-50. doi: 10.1056/NEJMra0906948. Review. No abstract available.

5.

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.

Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, Lieberman JA, Kennedy JL, Müller DJ.

Pharmacogenomics. 2010 Nov;11(11):1561-71. doi: 10.2217/pgs.10.123.

PMID:
21121776
6.

Effect of FTO, SH2B1, LEP, and LEPR polymorphisms on weight gain associated with antipsychotic treatment.

Perez-Iglesias R, Mata I, Amado JA, Berja A, Garcia-Unzueta MT, Martínez García O, Arranz MJ, Vazquez-Barquero JL, Crespo-Facorro B.

J Clin Psychopharmacol. 2010 Dec;30(6):661-6.

PMID:
21105276
7.
8.

Crystal structure of the FTO protein reveals basis for its substrate specificity.

Han Z, Niu T, Chang J, Lei X, Zhao M, Wang Q, Cheng W, Wang J, Feng Y, Chai J.

Nature. 2010 Apr 22;464(7292):1205-9. doi: 10.1038/nature08921. Epub 2010 Apr 7.

PMID:
20376003
9.

Implications of marked weight gain associated with atypical antipsychotic medications in children and adolescents.

Varley CK, McClellan J.

JAMA. 2009 Oct 28;302(16):1811-2. doi: 10.1001/jama.2009.1558. No abstract available.

PMID:
19861677
10.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

11.

Genetic variation in the hypothalamic pathways and its role on obesity.

van Vliet-Ostaptchouk JV, Hofker MH, van der Schouw YT, Wijmenga C, Onland-Moret NC.

Obes Rev. 2009 Nov;10(6):593-609. doi: 10.1111/j.1467-789X.2009.00597.x. Epub 2009 Jun 5. Review.

PMID:
19712437
12.

The genetic contribution to non-syndromic human obesity.

Walley AJ, Asher JE, Froguel P.

Nat Rev Genet. 2009 Jul;10(7):431-42. doi: 10.1038/nrg2594. Review.

PMID:
19506576
13.

Obesity among those with mental disorders: a National Institute of Mental Health meeting report.

Allison DB, Newcomer JW, Dunn AL, Blumenthal JA, Fabricatore AN, Daumit GL, Cope MB, Riley WT, Vreeland B, Hibbeln JR, Alpert JE.

Am J Prev Med. 2009 Apr;36(4):341-50. doi: 10.1016/j.amepre.2008.11.020.

PMID:
19285199
14.

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.

Need AC, Keefe RS, Ge D, Grossman I, Dickson S, McEvoy JP, Goldstein DB.

Eur J Hum Genet. 2009 Jul;17(7):946-57. doi: 10.1038/ejhg.2008.264. Epub 2009 Jan 21.

15.

Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.

Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, Krieg JC, Hebebrand J, Theisen FM.

J Psychiatr Res. 2009 Mar;43(6):620-6. doi: 10.1016/j.jpsychires.2008.11.001. Epub 2008 Dec 24.

PMID:
19110264
16.

Clinical risk factors, DNA variants, and the development of type 2 diabetes.

Lyssenko V, Jonsson A, Almgren P, Pulizzi N, Isomaa B, Tuomi T, Berglund G, Altshuler D, Nilsson P, Groop L.

N Engl J Med. 2008 Nov 20;359(21):2220-32. doi: 10.1056/NEJMoa0801869.

17.

A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms.

Gao X, Starmer J, Martin ER.

Genet Epidemiol. 2008 May;32(4):361-9. doi: 10.1002/gepi.20310.

PMID:
18271029
18.

Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion.

Kirchhoff K, Machicao F, Haupt A, Schäfer SA, Tschritter O, Staiger H, Stefan N, Häring HU, Fritsche A.

Diabetologia. 2008 Apr;51(4):597-601. doi: 10.1007/s00125-008-0926-y. Epub 2008 Feb 9.

PMID:
18264689
19.

Regulation of Fto/Ftm gene expression in mice and humans.

Stratigopoulos G, Padilla SL, LeDuc CA, Watson E, Hattersley AT, McCarthy MI, Zeltser LM, Chung WK, Leibel RL.

Am J Physiol Regul Integr Comp Physiol. 2008 Apr;294(4):R1185-96. doi: 10.1152/ajpregu.00839.2007. Epub 2008 Feb 6. Erratum in: Am J Physiol Regul Integr Comp Physiol. 2008 Oct;295(4):R1360-3.

20.

Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity.

Lindgren CM, McCarthy MI.

Nat Clin Pract Endocrinol Metab. 2008 Mar;4(3):156-63. doi: 10.1038/ncpendmet0723. Epub 2008 Jan 15. Review.

PMID:
18212765

Supplemental Content

Support Center